Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 25Pituitary Neoplasms 10Pheochromocytoma 10Carcinoma, Neuroendocrine 9Thyroid Neoplasms 8Sarcoma 8Thyroid Cancer, Papillary 6Paraganglioma 5Ovarian Neoplasms 5Neuroblastoma 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 4Parathyroid Neoplasms 4Pancreatic Neoplasms 4Osteosarcoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Adrenal Gland Neoplasms 4Thyroid Carcinoma, Anaplastic 3Stomach Neoplasms 3Prostatic Neoplasms 3Pituitary ACTH Hypersecretion 3Melanoma 3Head and Neck Neoplasms 3Cushing Syndrome 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Endocrine × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡